← Back to headlines
Krystal Biotech Beats Q4 Top-Line and Bottom-Line Estimates, Initiates FY26 Outlook
Krystal Biotech exceeded both revenue and earnings estimates for the fourth quarter and has initiated its financial outlook for fiscal year 2026.
17 Feb, 12:04 — 17 Feb, 12:04
ℹOnly 1 source covers this story
Read at source (1 outlet)
Related Stories
Gold price today, Monday, February 23: Gold opens above $5,100 after tariff ruling
just now
Standard Chartered Predicts Stablecoins to Hold $1 Trillion in T-Bills by 2028
just now
India and France Amend Double Taxation Avoidance Agreement
3m ago
Portugal's Non-Financial Sector Debt Falls to 277.9% of GDP in 2025
6m ago